Car Nk

EB-DUO-CAR-NK-CEA/GCC

EB-DUO-CAR-NK-CEA/GCC is flagged as a low confidence because it has an active early-phase oncology cell-therapy trial at Beijing Biotech, with a unlinked patent signal linked through public patent-search heuristics. Manual review is still required.

Asset overview

Program snapshot

Target: HER2

Cell type: NK_CELL

Indications: Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer

Sponsor: Beijing Biotech

Institution: Beijing Biotech

Clinical evidence

Trial footprint

Phase: Phase1

Status: Recruiting

Trial count: 1

Active trials: 0

First posted: May 15, 2026

Last updated: May 15, 2026

Signal summary

IP and BD posture

IP signal: Unlinked

BD label: Low Confidence

Confidence: Low

Manual review required: Yes

Scores

Deterministic scoring

Clinical translation3
IP linkage0
Licensing clarity2
Strategic interest4
Source

Public trial record

Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.

Open source study

NCT IDs: NCT07589517